Silverback Therapeutics

ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Seer

The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.

Biotech IPOs Stay Hot With Seer, Silverback Set To Trade

Silverback Therapeutics prices IPO at $21/share, will raise $241M in 4th Wash. state IPO of 2020

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Silverback f

Silverback Therapeutics Announces Pricing of Initial Public Offering

Silverback Therapeutics Inc. upsized its initial public offering to 10.00 million shares, and the expected pricing of the offering increased to between $19 and $20 a share. The Seattle-based biopharmaceutical company focused on cancer treatment had said earlier this week that it was offering 6.95 million shares and IPO was expected to price between $17 and $19 a share.

Silverback Therapeutics upsizes IPO, to now raise up to $200 million

News for Silverback Therapeutics Stock (SBTX)